Home › Companies › KAPA

Pipeline (13 active programs)

Capital (as filed)

Cash

$2.6M cash and cash equivalents · Jun 30, 2026 (10-Q)

Operating cash flow

−$1.0M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$2.6M cash per the update of Oct 6, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

• 2026-10-07 UPDATE: Kairos Pharma (KAPA) - The Control Arm Finally Shows Up 🔒 Paid
• 2026-08-18 Kairos Pharma (KAPA) - Scientific Deep Dive for ENV-105 and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Kairos Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-08-18 Avoid Kairos Pharma (KAPA) - Scientific Deep Dive for ENV-105 and Pipeline Products Recycled antibody with a 0-for-5 randomized record, zero objective responses in prostate cancer, a nine-patient dataset benchmarked against the wrong controls, and a balance sheet that cannot pay for already-ordered drug substance.
2. 2026-10-07 Watch UPDATE: Kairos Pharma (KAPA) - The Control Arm Finally Shows Up The randomized control arm is now public with a large headline gap (17.7 vs 2.0 months PFS, P=0.0008), warranting a watch-list upgrade, but missing arm sizes, hazard ratio, endpoint definition, and safety data prevent a buy call, and the balance sheet remains stressed.

• Avoid call · opened Aug 18, 2026 at $2.17 · closed Oct 7, 2026 (downgraded to WATCH from avoid) at $0.870 · -59.9% vs XBI -6.2%

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 5, 2026ReleaseKairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
• Nov 5, 20268-KCurrent report: other events · EX-99.1
• Nov 3, 2026ReleaseKairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
• Nov 3, 20268-KCurrent report: material agreement, other events · EX-99.1
• Oct 6, 2026ReleaseKairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer→ BD updateSummary on the 8-K
• Oct 6, 20268-KCurrent report: other events · EX-99.1→ BD updateKairos's randomized Phase 2 finally reported both arms: 17.7 months vs. 2 months, p=0.0008 — but the stock fell 25% on data that looks positive, and the devil is in what the press release doesn't say: n, patient count per arm, and a mid-trial protocol change that switches the backbone drug and moves enrollment earlier in the disease.BD extracted 1 program update from this document → KAPA pipeline
• Sep 23, 2026ReleaseKairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
• Sep 14, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• Sep 9, 2026ReleaseKairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
• Aug 21, 2026ReleaseKairos Pharma Announces 1-for-7 Reverse Stock Split
• Aug 21, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year, Reg FD disclosure · EX-99.1
• Aug 12, 202610-QQuarterly report
• Jul 22, 20268-KCurrent report: material agreement, other events · EX-99.1
• Jul 15, 20268-KCurrent report: other events · EX-99.1
• Jun 30, 20268-KCurrent report: shareholder vote
• Jun 4, 20268-KCurrent report: other events · EX-99.1
• May 26, 2026DEFA14AProxy soliciting material
• May 22, 2026DEF 14AProxy statement
• May 18, 20268-KCurrent report: other events · EX-99.1
• May 13, 202610-QQuarterly report
• Apr 1, 2026424B3Prospectus (resale / update)
• Apr 1, 2026424B3Prospectus (resale / update)
• Mar 31, 202610-KAnnual report
• Mar 2, 20268-KCurrent report: material agreement, other events · EX-99.1